Gregory Gotta

Gregory Gotta Jr. is a biotechnology business development professional at Editas Medicine, where he has held roles of increasing responsibility across R&D, alliance management, search and evaluation, licensing, and corporate strategy. With a scientific background in molecular biology, genetics, and genetic medicines, Gregory works at the intersection of emerging science and business strategy. His experience spans gene-editing technologies, RNA medicines, engineered cell therapies, and viral and nonviral delivery technologies. Gregory has been closely involved in evaluating and licensing CRISPR technologies, including institutional and corporate licensing arrangements. He partners cross-functionally with research, clinical, legal, finance, CMC, and commercial teams to assess new opportunities and help advance innovative therapeutic pipelines. He brings a practical perspective on how emerging technologies move from scientific concepts toward clinical and commercial application, and how partnerships can help translate breakthrough science into meaningful new medicines.